HTPN 083: Give PrEP a Shot

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP in HIV-uninfected men and transgender women who have sex with men.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094
https://www.hptn.org/research/studies/hptn083
https://giveprepashot.org/